1025 related articles for article (PubMed ID: 29217664)
41. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates.
Stramba-Badiale M; Nador F; Porta N; Guffanti S; Frediani M; Colnaghi C; Grancini F; Motta G; Carnelli V; Schwartz PJ
Am Heart J; 1997 Jan; 133(1):108-11. PubMed ID: 9006298
[TBL] [Abstract][Full Text] [Related]
42. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
43. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
44. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for QT prolongation associated with acute psychotropic drug overdose.
Miura N; Saito T; Taira T; Umebachi R; Inokuchi S
Am J Emerg Med; 2015 Feb; 33(2):142-9. PubMed ID: 25445869
[TBL] [Abstract][Full Text] [Related]
46. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
[TBL] [Abstract][Full Text] [Related]
47. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
48. QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy.
Feldman AE; Gidal BE
Epilepsy Behav; 2013 Mar; 26(3):421-6. PubMed ID: 23218812
[TBL] [Abstract][Full Text] [Related]
49. Psychotropics and sudden cardiac death.
Gören JL; Dinh TA
R I Med J (2013); 2013 Mar; 96(3):38-41. PubMed ID: 23641438
[TBL] [Abstract][Full Text] [Related]
50. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
Lindström E; Farde L; Eberhard J; Haverkamp W
Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
[TBL] [Abstract][Full Text] [Related]
51. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
Milic M; Bao X; Rizos D; Liu F; Ziegler MG
Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
[TBL] [Abstract][Full Text] [Related]
52. Corrected QT Interval Prolongation in Pediatric and Young Adult Patients on Methadone for Cancer-Related Pain.
Madden K; Jo E; Williams JL; Liu D; Bruera E
J Pain Symptom Manage; 2019 Oct; 58(4):678-684. PubMed ID: 31195079
[TBL] [Abstract][Full Text] [Related]
53. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
Vieweg WV; Wood MA
Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
[TBL] [Abstract][Full Text] [Related]
54. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
Glassman AH; Bigger JT
Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
[TBL] [Abstract][Full Text] [Related]
55. Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.
Michels G; Kochanek M; Pfister R
Med Klin Intensivmed Notfmed; 2016 May; 111(4):302-9. PubMed ID: 26340799
[TBL] [Abstract][Full Text] [Related]
56. Assessing QT interval prolongation and its associated risks with antipsychotics.
Nielsen J; Graff C; Kanters JK; Toft E; Taylor D; Meyer JM
CNS Drugs; 2011 Jun; 25(6):473-90. PubMed ID: 21649448
[TBL] [Abstract][Full Text] [Related]
57. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
Reddy S; Hui D; El Osta B; de la Cruz M; Walker P; Palmer JL; Bruera E
J Palliat Med; 2010 Jan; 13(1):33-8. PubMed ID: 19824814
[TBL] [Abstract][Full Text] [Related]
58. [Lengthening of QT interval by antipsychotic drugs].
Haverkamp W; Deuschle M
Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
[TBL] [Abstract][Full Text] [Related]
59. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
Singh M; Arora R; Jawad E
Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
[TBL] [Abstract][Full Text] [Related]
60. Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.
Morris AD; Chen J; Lau E; Poh J
Can J Hosp Pharm; 2016; 69(3):224-30. PubMed ID: 27403002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
